Menu
Enrolling by invitation NCT07483424

Determination of Clinical Phenotypes of Intrauterine Growth Restriction in Term Infants Based on Body Composition

Observational Intrauterine Growth Restriction (IUGR)

For patients and families

In plain language

An automatic summary of structured registry data. It is an orientation aid, not a substitute for the official protocol or a physician assessment.

What is being studied
The protocol lists: Small for gestational age (SGA) infants, Adequate for gestational age (AGA) infants.
Who it may be relevant to
Registry conditions: Intrauterine Growth Restriction (IUGR). Basic parameters: 37 Weeks — 41 Weeks · All.
What needs checking
Age, condition and sex are only basic indicators. Prior treatment, laboratory values and other mandatory requirements appear in the eligibility criteria below.
Where it takes place
Portugal
Next step
Save the trial, show it to the treating physician, and confirm current recruitment with the study center. Costs, documents and travel →
Official title

Determination of Clinical Phenotypes of Intrauterine Growth Restriction in Term Infants Based on Body Composition. A Potential Contribution to Nutritional Management.

Overview

Intrauterine growth restriction (IUGR) is defined as the inability of the fetus to fulfill its genetic growth potential. "Small for gestational age" (SGA) is the most commonly used indicator for diagnosing IUGR. However, this definition does not consider intrauterine growth trajectory or physical characteristics at birth. SGA is based on the relationship between birth weight and gestational age, and does not address anthropometric measurements at birth or prenatal indicators, such as biometric, biophysical, and Doppler velocimetry abnormalities. SGA infants may constitute intrauterine growth restricted as well as constitutionally small infants. This distinction can be made more accurately by complementary assessment of body composition. The clinical meaning of each group identified by body composition will be assessed by the evolution until 3-months of age. The feeding pattern and composition will be considered a major postnatal exposure. Accurate classification of IUGR profiles is essential to ensure appropriate nutritional intervention.

Detailed description

Study design: This is a single-center prospective observational, cohort study of full-term infants born with intrauterine growth restriction (IUGR) and their lactating mothers.

Study period: A consecutive recruitment of participants will be conducted over 18 months (from November 19, 2025). Eligible children, whose parents accepted the invitation to participate, will be recruited in a follow-up study until they are 3 months old.

Settings: Neonatology Unit, Prenatal Diagnostic Center and Human Milk Bank at Maternidade Dr. Alfredo da Costa, Unidade Local de Saúde São José, Lisbon. Nutrition Laboratory of Hospital Dona Estefânia, Unidade Local de Saúde São José, Lisbon, Portugal.

Variables in study:

* Mother's retrieved demographic and clinical variables will include: mother's age, height, reported body weight closer to the beginning of pregnancy, body weight gain during pregnancy, pathological conditions during pregnancy (diabetes mellitus type I and type II, gestational diabetes, gestational hypertension, hypertension, pre-eclampsia, chronic renal disease, systemic lupus erythematosus, anaemia or other conditions). * Obstetrics' Doppler velocimetry serial ultrasounds will be analysed. The data retrieved will include gestational age at ultrasound date, fetal abdominal circumference, femur length, head circumference, estimated fetal weight, pulsatility index of umbilical artery, middle cerebral artery, venous duct and uterine artery. * Mothers dietary habits: A semi-quantitative food frequency questionnaire consisting of 86 food items, validated for Portuguese pregnant women, will be applied one week after birth to assess food intake during the second and third trimesters of pregnancy. * Breast milk macronutrient and energy content: The breast milk macronutrient and energy content will be analyzed using the Miris® Human Milk analyzer (Miris AB, Uppsala, Sweden). Mothers will be asked to save circa 4 cc of midfeeding breast milk during the noon feeding, as a systematic sampling of milk collected through 24 hours, in order to minimize daily variability of breast milk composition. Before each use, the analyzer will be calibrated using the standard calibration solution. The breast milk composition will be expressed in densities: Kcal/dL of energy and g/dL of fat, total and true protein, carbohydrates, and ashes. * Neonatal variables: gestational age at birth, sex, parity, birth weight, height and head circumference, gestational age adequacy. * Body composition assessment: Body composition assessment will be conducted using a Displacement Plethysmograph (Pea Pod, Cosmed, Italy), which is validated for newborns. Subsequent assessments will be performed by the same observer at 1 week after discharge, 1 month and 3 months of age (+/- 1 week). The equipment automatically provides fat mass (FM), fat-free mass (FFM) and fat mass percentage (%FM). The same observer will measure length, and this measurement will be used to calculate the fat mass index (FMI). Adiposity will be defined by %FM (FM (kg)/body mass (kg)) and FMI (FM (kg)/length (m²)).

Estimate of sample size: Assuming the highest probability (2:1) of reduced adiposity in small-for-gestational-age (SGA) infants with reduced fat-free mass (FFM), SGA infants with reduced adiposity, appropriate-for-gestational-age (AGA) infants with fetal growth deceleration and/or Doppler velocimetry abnormalities with reduced FFM, and AGA infants with fetal growth deceleration and/or Doppler velocimetry abnormalities with reduced adiposity, and considering a 95% confidence interval, the expected sample size is 145 SGA infants and 145 AGA infants.

Comparison groups: Body composition will be compared between the following IUGR profiles: SGA infants without fetal growth deceleration or Doppler velocimetry abnormalities; SGA with fetal growth deceleration or Doppler velocimetry abnormalities; AGA with fetal growth deceleration or Doppler velocimetry abnormalities; SGA with reduced FFM (Fat-free-mass); SGA with reduced adiposity; AGA with fetal growth deceleration and/or Doppler velocimetry abnormalities with reduced FFM. AGA with fetal growth deceleration and/or Doppler velocimetry abnormalities with reduced adiposity.

Interventions

  • Dietary supplement Small for gestational age (SGA) infants
    * Body composition assessment will be conducted using a Displacement Plethysmograph (Pea Pod, Cosmed, Italy), which is validated for newborns (Ellis et al., 2007). Subsequent assessments will be performed by the same observer at 1 week after discharge, 1 month and 3 months of age. * At birth and during body composition evaluations, anthropometric measurements (body weight, length and head circumference) will be measured. * The breast milk macronutrient and energy content will be analyzed using t
  • Dietary supplement Adequate for gestational age (AGA) infants
    * Body composition assessment will be conducted using a Displacement Plethysmograph (Pea Pod, Cosmed, Italy), which is validated for newborns (Ellis et al., 2007). Subsequent assessments will be performed by the same observer at 1 week after discharge, 1 month and 3 months of age. * At birth and during body composition evaluations, anthropometric measurements (body weight, length and head circumference) will be measured. * The breast milk macronutrient and energy content will be analyzed using t

Primary outcome measures

  • Body composition assessment - Fat mass (FM) [Time frame: Fat mass will be assessed 1 week after discharge, 1 month of age and 3 months of age]
  • Body composition assessment - Fat-free mass (FFM) [Time frame: Fat-free mass will be assessed 1 week after discharge, 1 month of age and 3 months of age]
  • Body composition assessment - Fat mass index (FMI) [Time frame: Fat mass index will be calculated 1 week after discharge, 1 month of age and 3 months of age]
  • Body composition assessment - Adiposity (%FM) [Time frame: Adiposity will be assessed 1 week after discharge, 1 month of age and 3 months of age]
Secondary outcome measures (12)
  • Neonatal anthropometry - Body weight [Time frame: At birth, 1 week after discharge, 1 month of age and 3 months of age]
  • Neonatal anthropometry - Length [Time frame: Length will be measured at birth, 1 week after discharge, 1 month of age and 3 months of age]
  • Neonatal anthropometry - Head circumference [Time frame: Head circumference will be measured at birth, 1 week after discharge, 1 month of age and 3 months of age]
  • Breast milk energy content [Time frame: Weekly from birth until 3 months of age]
  • Breast milk macronutrient concentration [Time frame: Weekly from birth until 3 months of age]
  • Mothers dietary habits - Mother energy intake [Time frame: Assessed once at recruitment, within the first week after birth]
  • Maternal dietary habits - Maternal macronutrient intake [Time frame: Assessed once at recruitment, within the first week after birth]
  • Prenatal fetal biometry and Doppler percentiles [Time frame: Assessed retrospectively during the study period]
  • Maternal demographic and clinical variables - Maternal age [Time frame: At birth (time of recruitment)]
  • Mother's demographic and clinical variables - Maternal height [Time frame: At birth (time of recruitment)]
  • Mother's demographic and clinical variables - Pre-pregnancy weight [Time frame: At birth (time of recruitment)]
  • Mother's demographic and clinical variables - Postpartum weight [Time frame: From recruitment until 3 months after birth]

Eligibility criteria

Inclusion criteria

  • IUGR and term GA (37+0/7 to 41+6/7 weeks of gestation)

Exclusion criteria

  • Eligible fetuses with congenital malformations
  • Eligible fetuses with genetic mutations.
  • Eligible infants with congenital malformations
  • Eligible intants with inborn errors of metabolism.
  • Infants who become ill and require hospitalization during the study period
  • Infants who die during the study period
  • Parents or legal guardians who do not agree to participate
  • Parents or legal guardians who abandon the study.

Criteria are shown verbatim from the registry (in English). Final eligibility is always assessed by the study center.

Healthy volunteers: Yes

Study design

Observational model
Cohort

Study locations

Portugal · 1 center
  • Unidade Local de Saúde São José — Lisbon

Publications

  • Pinto E, Severo M, Correia S, dos Santos Silva I, Lopes C, Barros H. Validity and reproducibility of a semi-quantitative food frequency questionnaire for use among Portuguese pregnant women. Matern Child Nutr. 2010 Apr;6(2):105-19. doi: 10.1111/j.1740-8709.2009.00199.x. PMID 20624208
  • Goswami I, Rochow N, Fusch G, Liu K, Marrin ML, Heckmann M, Nelle M, Fusch C. Length Normalized Indices for Fat Mass and Fat-Free Mass in Preterm and Term Infants during the First Six Months of Life. Nutrients. 2016 Jul 8;8(7):417. doi: 10.3390/nu8070417. PMID 27399768
  • Ellis KJ, Yao M, Shypailo RJ, Urlando A, Wong WW, Heird WC. Body-composition assessment in infancy: air-displacement plethysmography compared with a reference 4-compartment model. Am J Clin Nutr. 2007 Jan;85(1):90-5. doi: 10.1093/ajcn/85.1.90. PMID 17209182
  • Cardoso M, Virella D, Papoila AL, Alves M, Macedo I, E Silva D, Pereira-da-Silva L. Individualized Fortification Based on Measured Macronutrient Content of Human Milk Improves Growth and Body Composition in Infants Born Less than 33 Weeks: A Mixed-Cohort Study. Nutrients. 2023 Mar 22;15(6):1533. doi: 10.3390/nu15061533. PMID 36986263
  • Cardoso M, Virella D, Macedo I, Silva D, Pereira-da-Silva L. Customized Human Milk Fortification Based on Measured Human Milk Composition to Improve the Quality of Growth in Very Preterm Infants: A Mixed-Cohort Study Protocol. Int J Environ Res Public Health. 2021 Jan 19;18(2):823. doi: 10.3390/ijerph18020823. PMID 33477964
  • Czosnykowska-Lukacka M, Krolak-Olejnik B, Orczyk-Pawilowicz M. Breast Milk Macronutrient Components in Prolonged Lactation. Nutrients. 2018 Dec 3;10(12):1893. doi: 10.3390/nu10121893. PMID 30513944

Identifiers

NCT: NCT07483424 · CHULC.CI.658.2026

Primary sources (government registries)

View this study on ClinicalTrials.gov ↗